ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC), a clinical stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, announced today that Manish Singh, PhD, President and Chief Executive Officer of the Company will be presenting at the 2012 BIO International Convention being held June 18
, 2012, at the Boston Convention and Exhibition Center in Boston, Massachusetts.
The presentation is part of the BIO Business Forum track, and will take place on Tuesday, June 19
at 9:45 a.m. EST in the Red Sox Room.
The BIO International Convention brings together thousands of companies and industry professionals from around the world, in order to forge strategic partnerships and share valuable information. The event is designed to create opportunities for education, networking, BIO Business Forum partnering, and a chance for the 1,800 participating companies to demonstrate their technological advances, products, and services during the BIO Exhibition.
About ImmunoCellular Therapeutics, Ltd.
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit